Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Luke T. Nordquist, Neal D. Shore, Johann S. De Bono, Shilpa Gupta, William R. Berry, Silke Gillessen, Glenn Liu, Nicholas J. Vogelzang, Eleni Efstathiou, Mark T. Fleming, Daniel J. George, John C. Araujo, Jingsong Zhang, Michael R Kurman, Joel Robert Eisner, William R. Moore
Institutions: Urology Cancer Center and GU Research Network, Carolina Urologic Research Center, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Moffitt Cancer Center, Duke Medical Center, Kantonsspital St. Gallen, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Comprehensive Cancer Centers of Nevada, National and Kapodistrian University of Athens, Alexandra Hospital, The University of Texas MD Anderson Cancer Center, Innocrin Pharmaceuticals (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2590626300